At CFO (Boardroom Media) we track over 1,000,000 startups and over 5,000,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top Paris based CFO’ operating in the Medical space. If you think a CFO’ is missing from this list, feel free to contact our editor on [email protected]
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
CFO of GenSight Biologics
Thomas Gidoin has been GenSight Biologics’ Chief Financial Officer since June 2015. From 2012 to mid-2015, Thomas was Vice President Finance at DBV Technologies S.A., where he led the Corporate Finance team and participated in public offerings and private placements, including the dual listing of DBV Technologies on the Nasdaq Global Select Market in 2014. From 2008 to 2011, he served in various positions at Ipsen S.A., including UK Operations Controller in London and Senior Financial Analyst in the Global Operations division in Paris. He started his career in audit at Ernst & Young. Thomas received a Master’s degree in International Finance from ESGF Paris and a Master’s degree in International Management from Neoma Business School in France.
Follow Thomas Gidoin:
About GenSight Biologics: GenSight Biologics develops gene therapy-based treatments for retinal degenerative diseases.
CFO of Corwave
Zina Hamoumi brings more than 15 years of experience in corporate finance and accounting, including 7 years in the life sciences sector. She started her career at PwC in the audit practice, before moving to operational roles at Mexx (retail) and then Lundbeck France (pharmaceuticals), where she was Head of Finance and Logistics, overseeing financial operations that included sales, production, and R&D activities. She subsequently joined Victoria Beckham Ltd (fashion/retail) in London in 2014 as Finance Director. She supported the fast-growing business, put in place solid financial processes, and played an instrumental role in setting up a private equity round of funding. Zina holds a Msc in Management from EM Lyon business school.
Follow Zina Hamoumi:
About Corwave: CorWave is a medical device company developing innovative heart pumps.
Chief Financial Officer of CellNovo
Erwan brings over 20 years of experience in finance, biotechnology and corporate development. Before joining Cellnovo, Erwan was Chief Financial Officer of Genomic Vision (Euronext: GV), a position he had held since 2009. He was also VP of Corporate Development until 2015, undertaking financing operations such as the Company’s initial public offering. He has also worked at Syndex, and co-founded Cytomics Pharmaceuticals, a biotechnology company specialising in the discovery of new medicines.
Follow Erwan Martin:
About CellNovo: CellNovo is a medical device company developing a wireless therapeutic system for diabetic patients.
CFO of EOS Imaging
Valérie Worrall has over 20 years’ experience in Finance in the Healthcare industry. She had a long tenure with Novartis and worked in a number of their divisions. Her international career led her to the United States, South East Asia, Switzerland, Great Britain and France. Most recently, she was the CFO of Balt, a French medical device company. She joined EOS imaging in 2018 as the Chief Financial Officer. Valérie Worrall has a Masters in Management from HEC Paris.
Follow Valerie Worrall:
About EOS Imaging: EOS imaging designs, develops, and markets EOS®, a revolutionary and patented medical imaging system, based on technology.
Chief Financial Officer of Antabio
Gordon Waldron is the Chief Financial Officer at Antabio. Prior to joining SuperSonic Imagine in September 2010, Mr. Waldron spent five years as CFO for the French biotech company Novexel where he raised €50 million in 2006, negotiated a preclinical license agreement which brought the company a €75 million upfront payment in 2008 and directed a trade sale process resulting in the acquisition of Novexel by AstraZeneca for cash consideration of approximately $500 million in 2009. Before Novexel, he spent eight years as VP Finance with Synt:em (Nimes, France) where he raised €32 million in three financing rounds. Gordon also spent five years with Texas Instruments, first as Finance Director for a French subsidiary, then as Group Finance Manager (based in the UK) covering 17 entities and a distributor network for Texas Instruments Software in the Europe, Middle East and Africa territories. Mr. Waldron started his career with Spie Batignolles at its head office near Paris before becoming a controller of the company’s US subsidiaries based in Pittsburgh. He graduated from Duke University (USA) in 1988 and has both American and British nationalities.
Follow Gordon Waldron:
About Antabio, SuperSonic Imagine: Antabio is a private biopharmaceutical company developing antibacterial resistance-breakers in areas of highest medical need.
Co-Founder & CFO of Enovap
Follow Valentin Delahaye:
About Enovap: Enovap is a intelligent dual-tank e-cigarette, designed and built to help smokers and vapers get full control of their nicotine intake.
Group Chief Financial and Operating Officer of InVivo
Follow Maha Fournier:
About InVivo: InVivo helps agriculture cooperation regain their rightful place in the global food value chain.
Chief Financial Officer of Mauna Kea Technologies
Prior to joining Mauna Kea Technologies, Christophe Lamboeuf served as the Chief Financial Officer and Deputy Chief Executive Officer of Intrasense, a French publicly-traded company developing a medical imaging visualization and analysis software suite. He was involved in a number of capital raises following the company’s initial public offering in 2012. He also has experience working with General Electric, Ricoh, CS Telecom and Toshiba. Christophe is a chartered accountant and holds an advanced degree (DESS) in Finance from the IAE Graduate School of Management and a Master in Economics.
Follow Christophe Lamboeuf:
About Mauna Kea Technologies: Mauna Kea Technologies specializes in designing, developing, and selling optical biopsy devices and tools.